In this episode, we explore the groundbreaking impact of targeted therapy for MET amplification in non-small cell lung cancer (NSCLC), focusing on how it has transformed the treatment landscape for patients with advanced, metastatic disease. We’ll delve into the science behind MET amplification, explaining how targeting its overactive signaling can hinder tumor growth and potentially offer new hope for patients facing stage IV NSCLC. 

By the end of this episode, our goal is to equip you with the knowledge to discuss targeted therapies with confidence, empowering you to make informed decisions with your healthcare team regarding the most appropriate treatment options for your individual needs.

Cre: Patient Resource

See More HERE